CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis
about
Liver-specific beta-catenin knockout mice exhibit defective bile acid and cholesterol homeostasis and increased susceptibility to diet-induced steatohepatitisRedox mechanisms in hepatic chronic wound healing and fibrogenesisMeasurement of the total antioxidant response using a novel automated method in subjects with nonalcoholic steatohepatitis.Animal Models of Nonalcoholic Steatohepatitis: Eat, Delete, and InflameModulation of hepatic lipid metabolism by olive oil and its phenols in nonalcoholic fatty liver diseaseFunctional roles of protein nitration in acute and chronic liver diseasesBeing right on Q: shaping eukaryotic evolutionLiver-specific inactivation of the Nrf1 gene in adult mouse leads to nonalcoholic steatohepatitis and hepatic neoplasiaLipotoxic effect of p21 on free fatty acid-induced steatosis in L02 cellsInhibitory effects of Japanese herbal medicines sho-saiko-to and juzen-taiho-to on nonalcoholic steatohepatitis in miceIncreased cytochrome P-450 2E1 expression sensitizes hepatocytes to c-Jun-mediated cell death from TNF-alphaThe role of ethanol metabolism in development of alcoholic steatohepatitis in the ratA targeted apoB38.9 mutation in mice is associated with reduced hepatic cholesterol synthesis and enhanced lipid peroxidationAutophagy regulates lipid metabolismLipotoxicity in the liver.In vitro and in vivo models of non-alcoholic fatty liver disease (NAFLD).Altered expression patterns of lipid metabolism genes in an animal model of HCV core-related, nonobese, modest hepatic steatosis.IL-6 deficiency attenuates murine diet-induced non-alcoholic steatohepatitisProtective effects of tiopronin against high fat diet-induced non-alcoholic steatohepatitis in rats.Role of adipose tissue in methionine-choline-deficient model of non-alcoholic steatohepatitis (NASH)Bofutsushosan, a Japanese herbal (Kampo) medicine, attenuates progression of nonalcoholic steatohepatitis in mice.PPAR/RXR Regulation of Fatty Acid Metabolism and Fatty Acid omega-Hydroxylase (CYP4) Isozymes: Implications for Prevention of Lipotoxicity in Fatty Liver DiseaseHepatoprotective effects of S-adenosyl-L-methionine against alcohol- and cytochrome P450 2E1-induced liver injury.Discovering networks of perturbed biological processes in hepatocyte culturesLiver proteomic response to hypertriglyceridemia in human-apolipoprotein C-III transgenic mice at cellular and mitochondrial compartment levelsBariatric surgery-induced weight loss reduces hepatic lipid peroxidation levels and affects hepatic cytochrome P-450 protein content.Reactive oxygen and nitrogen species in steatotic hepatocytes: a molecular perspective on the pathophysiology of ischemia-reperfusion injury in the fatty liver.High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis.Fatty liver and fibrosis in glycine N-methyltransferase knockout mice is prevented by nicotinamide.Bimodal targeting of microsomal cytochrome P450s to mitochondria: implications in drug metabolism and toxicityRegulatable fatty acid transport mechanisms are central to the pathophysiology of obesity, fatty liver, and metabolic syndrome.Insulin- and leptin-regulated fatty acid uptake plays a key causal role in hepatic steatosis in mice with intact leptin signaling but not in ob/ob or db/db mice.Oral N-acetylcysteine rescues lethality of hepatocyte-specific Gclc-knockout mice, providing a model for hepatic cirrhosis.JNK regulation of hepatic manifestations of the metabolic syndrome.Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy.Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress.Diet-induced obesity is associated with hyperleptinemia, hyperinsulinemia, hepatic steatosis, and glomerulopathy in C57Bl/6J miceControlled-release mitochondrial protonophore reverses diabetes and steatohepatitis in rats.Systems level metabolic phenotype of methotrexate administration in the context of non-alcoholic steatohepatitis in the ratNonalcoholic steatosis and steatohepatitis. V. Mitochondrial dysfunction in steatohepatitis.
P2860
Q24645373-A655C24D-A89C-410F-85F1-C5EB1042E2D2Q24656684-8D416A61-BF29-4E71-ABA8-DB7A53DA177DQ24815160-3EBE682A-54F6-4875-82EF-511B056DD39AQ26775571-FEF3719B-DFB3-4193-8F37-3C5EABCED107Q26827450-C04BDF97-AD53-415D-95DC-85794FC6EF14Q27008888-526B5A7A-734F-4BAB-A4A8-23F7B09E77CBQ28077397-D5BFBF12-0F8B-4D44-A150-D444974D8366Q28237402-E287BD6F-89D0-483A-9BD7-C2BCD8DF15DBQ28538284-9B4EF694-989A-4F71-8759-AFDCB9FBB6DAQ28539042-3D2D5D5D-7BE0-4A7A-AD43-4CDC3988F6B2Q28567149-77AF0222-56DC-40E5-A584-0CE8B0A2D7ADQ28576202-2FF59FAB-289A-45B0-89EA-8FEF74BB027AQ28585589-BE6CD772-BB74-4867-942B-40B2A2EED1BCQ29547421-C50589B8-447A-4C95-9D55-989DC16353C6Q30355131-C7566B5F-CA41-4A63-8B67-707149E7B170Q30452333-E23B2DE7-230D-40D3-B7A3-5A5ABAD9E7C5Q33321721-B0AC1C2F-1758-4803-8A23-A955FEEBBF31Q33516564-66E434AE-00FC-4EBC-B3CD-4543F4E2A7C7Q33567477-E4DE5648-CEC3-495E-8703-2D3B86D61822Q33665070-E24ED1BA-10B3-4416-B8CC-F21D27621FD7Q33722396-54007E86-F0E1-4986-83B4-998B49F903F4Q33734125-668FDF36-D0E4-42A0-865F-DF7A395719EFQ33742463-98414127-CA3B-4B86-B0D5-154F1351258CQ33796560-40064ABA-A10A-46BE-8A74-AA5F81FCC09BQ33958622-0761B05F-A79B-4609-BC7D-DBBF816FAF8FQ33990270-E14B963A-DA75-4089-B371-497BFE18E68DQ34009236-C76F8DF7-2920-4093-A395-F9B64762D4A1Q34023013-3D94E687-6794-40C7-BDE3-7A682ECC2D43Q34065528-80802428-A528-49FA-94B0-EE3C67C0E846Q34134358-78DCA53B-FFB7-4C15-9192-62F2C9EDCBD4Q34207748-722E0A80-F6BF-42B4-9E18-1E0A4EA1EEB8Q34212126-88F31188-BD20-4CD8-8D84-0CBA0847093CQ34267952-2CE8DD81-8B03-4DF5-A72B-312EDB0160A6Q34348797-DBF8BA7B-7A58-44BA-82B5-1EA4C5693355Q34368342-796AE19A-4424-423F-8DF1-0937BA95783DQ34415177-146603CC-699D-4293-931A-207D1F27F920Q34448415-398013E8-1A00-412E-B825-2D9824BC9209Q34464742-A596EA71-770C-47B2-8AA4-30EA99904F7DQ34483949-AE5ABDBD-1135-443A-BEAC-73AAEF93C0EBQ34502805-7D067574-2E73-4BB2-B07A-76547746801A
P2860
CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis
description
2000 nî lūn-bûn
@nan
2000 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
name
CYP2E1 and CYP4A as microsomal ...... e nonalcoholic steatohepatitis
@ast
CYP2E1 and CYP4A as microsomal ...... e nonalcoholic steatohepatitis
@en
CYP2E1 and CYP4A as microsomal ...... e nonalcoholic steatohepatitis
@nl
type
label
CYP2E1 and CYP4A as microsomal ...... e nonalcoholic steatohepatitis
@ast
CYP2E1 and CYP4A as microsomal ...... e nonalcoholic steatohepatitis
@en
CYP2E1 and CYP4A as microsomal ...... e nonalcoholic steatohepatitis
@nl
prefLabel
CYP2E1 and CYP4A as microsomal ...... e nonalcoholic steatohepatitis
@ast
CYP2E1 and CYP4A as microsomal ...... e nonalcoholic steatohepatitis
@en
CYP2E1 and CYP4A as microsomal ...... e nonalcoholic steatohepatitis
@nl
P2093
P2860
P356
P1476
CYP2E1 and CYP4A as microsomal ...... e nonalcoholic steatohepatitis
@en
P2093
F J Gonzalez
G C Farrell
G R Robertson
I A Leclercq
P2860
P304
P356
10.1172/JCI8814
P407
P577
2000-04-01T00:00:00Z